Loading...

Probi

OTCPK:PBBI.F
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBBI.F
OTCPK
SEK4B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
PBBI.F Share Price and Events
7 Day Returns
0%
OTCPK:PBBI.F
0.3%
US Biotechs
-1.4%
US Market
1 Year Returns
-
OTCPK:PBBI.F
-4.8%
US Biotechs
1.6%
US Market
PBBI.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Probi (PBBI.F) 0% 4.7% - - - -
US Biotechs 0.3% -2.6% -6% -4.8% 3.6% 11%
US Market -1.4% -3.9% 0.1% 1.6% 33.2% 38.2%
1 Year Return vs Industry and Market
  • No trading data on PBBI.F.
  • No trading data on PBBI.F.
Price Volatility
PBBI.F
Industry
5yr Volatility vs Market

Value

 Is Probi undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Probi to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Probi.

OTCPK:PBBI.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:PBBI.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.384 (1 + (1- 22%) (1.47%))
1.268
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.27
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.268 * 5.96%)
10.29%

Discounted Cash Flow Calculation for OTCPK:PBBI.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Probi is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:PBBI.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 10.29%)
2019 87.50 Analyst x2 79.34
2020 123.00 Analyst x2 101.13
2021 155.50 Analyst x2 115.92
2022 167.43 Est @ 7.67% 113.18
2023 177.79 Est @ 6.19% 108.97
2024 186.95 Est @ 5.15% 103.90
2025 195.22 Est @ 4.42% 98.38
2026 202.87 Est @ 3.92% 92.70
2027 210.09 Est @ 3.56% 87.04
2028 217.05 Est @ 3.31% 81.54
Present value of next 10 years cash flows SEK982.09
OTCPK:PBBI.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK217.05 × (1 + 2.73%) ÷ (10.29% – 2.73%)
SEK2,951.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK2,951.04 ÷ (1 + 10.29%)10
SEK1,108.61
OTCPK:PBBI.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK982.09 + SEK1,108.61
SEK2,090.70
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK2,090.70 / 11.39
SEK183.49
OTCPK:PBBI.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:PBBI.F represents 0.10948x of OM:PROB
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.10948x
Value per Share
(Listing Adjusted, USD)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 183.49 x 0.10948
$20.09
Value per share (USD) From above. $20.09
Current discount Discount to share price of $38.21
= -1 x ($38.21 - $20.09) / $20.09
-90.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Probi is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Probi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Probi's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:PBBI.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK7.15
OM:PROB Share Price ** OM (2019-05-07) in SEK SEK349
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.23x
United States of America Market PE Ratio Median Figure of 3,086 Publicly-Listed Companies 17.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Probi.

OTCPK:PBBI.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:PROB Share Price ÷ EPS (both in SEK)

= 349 ÷ 7.15

48.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Probi is overvalued based on earnings compared to the US Biotechs industry average.
  • Probi is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Probi's expected growth come at a high price?
Raw Data
OTCPK:PBBI.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 48.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
12.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.14x
United States of America Market PEG Ratio Median Figure of 2,121 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

OTCPK:PBBI.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 48.8x ÷ 12.9%

3.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Probi is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Probi's assets?
Raw Data
OTCPK:PBBI.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK93.90
OM:PROB Share Price * OM (2019-05-07) in SEK SEK349
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,208 Publicly-Listed Companies 1.8x
OTCPK:PBBI.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:PROB Share Price ÷ Book Value per Share (both in SEK)

= 349 ÷ 93.90

3.72x

* Primary Listing of Probi.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Probi is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Probi's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Probi has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Probi expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Probi expected to grow at an attractive rate?
  • Probi's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Probi's earnings growth is positive but not above the United States of America market average.
  • Probi's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:PBBI.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:PBBI.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 12.9%
OTCPK:PBBI.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 12.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:PBBI.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:PBBI.F Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,056 132 1
2022-12-31 997 123 1
2021-12-31 883 189 159 2
2020-12-31 766 152 128 2
2019-12-31 650 111 75 2
OTCPK:PBBI.F Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 623 154 81
2018-12-31 604 128 76
2018-09-30 561 120 53
2018-06-30 525 98 34
2018-03-31 544 100 29
2017-12-31 612 146 69
2017-09-30 687 166 98
2017-06-30 643 136 117
2017-03-31 544 127 118
2016-12-31 443 90 102
2016-09-30 286 52 74
2016-06-30 248 74 60

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Probi's earnings are expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
  • Probi's revenue is expected to grow by 12.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:PBBI.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Probi Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PBBI.F Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 11.55 11.55 11.55 1.00
2022-12-31 10.80 10.80 10.80 1.00
2021-12-31 13.93 17.86 9.99 2.00
2020-12-31 11.24 14.09 8.38 2.00
2019-12-31 6.58 8.26 4.90 2.00
OTCPK:PBBI.F Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 7.15
2018-12-31 6.69
2018-09-30 4.68
2018-06-30 2.99
2018-03-31 2.57
2017-12-31 6.06
2017-09-30 8.77
2017-06-30 11.02
2017-03-31 11.73
2016-12-31 10.73
2016-09-30 8.17
2016-06-30 6.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Probi is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Probi's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Probi has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Probi performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Probi's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Probi's year on year earnings growth rate has been positive over the past 5 years.
  • Probi's 1-year earnings growth exceeds its 5-year average (178.6% vs 19.5%)
  • Probi's earnings growth has exceeded the US Biotechs industry average in the past year (178.6% vs 54.9%).
Earnings and Revenue History
Probi's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Probi Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:PBBI.F Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 623.08 81.48 149.56 30.92
2018-12-31 604.12 76.25 146.55 32.73
2018-09-30 560.62 53.33 139.40 35.02
2018-06-30 525.30 34.03 139.19 33.63
2018-03-31 544.05 29.25 139.00 35.14
2017-12-31 612.24 69.09 138.45 36.61
2017-09-30 686.87 98.25 147.17 40.91
2017-06-30 642.57 117.15 137.64 40.52
2017-03-31 543.86 118.06 121.89 40.25
2016-12-31 443.48 101.85 102.81 36.88
2016-09-30 285.71 74.45 52.70 54.26
2016-06-30 248.36 59.88 48.61 47.85
2016-03-31 234.06 53.60 52.91 38.33
2015-12-31 215.98 49.04 57.07 30.61
2015-09-30 219.69 51.68 82.00
2015-06-30 204.89 45.59 76.37
2015-03-31 177.79 39.10 67.17
2014-12-31 135.24 21.77 59.87
2014-09-30 121.73 19.01 58.00
2014-06-30 109.20 15.66 56.29
2014-03-31 104.25 15.17 55.18
2013-12-31 103.55 15.05 54.69
2013-09-30 103.49 14.58 56.19
2013-06-30 100.47 13.83 54.67
2013-03-31 95.44 11.98 55.91
2012-12-31 100.39 13.51 58.36
2012-09-30 99.24 11.05 56.91
2012-06-30 99.67 12.59 56.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Probi has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Probi used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Probi's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Probi's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Probi has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Probi's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Probi's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Probi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Probi's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Probi's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Probi Company Filings, last reported 1 month ago.

OTCPK:PBBI.F Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,069.87 58.62 168.80
2018-12-31 1,028.40 118.48 199.30
2018-09-30 992.28 131.33 182.92
2018-06-30 971.52 191.85 194.56
2018-03-31 899.24 178.81 160.33
2017-12-31 884.74 175.87 155.55
2017-09-30 874.03 173.08 142.89
2017-06-30 895.47 180.69 128.59
2017-03-31 938.48 221.81 149.49
2016-12-31 892.07 225.76 103.14
2016-09-30 250.28 0.00 967.61
2016-06-30 222.11 0.00 169.43
2016-03-31 214.18 0.00 153.07
2015-12-31 187.24 0.00 143.02
2015-09-30 184.52 0.00 143.03
2015-06-30 171.38 0.00 121.55
2015-03-31 168.32 0.00 126.67
2014-12-31 145.95 0.00 108.18
2014-09-30 140.59 0.00 97.62
2014-06-30 133.54 0.00 94.34
2014-03-31 136.06 0.00 94.89
2013-12-31 131.03 0.00 91.30
2013-09-30 128.41 0.00 91.41
2013-06-30 124.71 0.00 87.25
2013-03-31 127.72 0.00 95.92
2012-12-31 122.82 0.00 87.29
2012-09-30 120.67 0.00 86.13
2012-06-30 117.72 0.00 83.37
  • Probi's level of debt (5.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 5.5% today).
  • Debt is well covered by operating cash flow (263.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 29x coverage).
X
Financial health checks
We assess Probi's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Probi has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Probi's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Probi dividends. Estimated to be 0.47% next year.
If you bought $2,000 of Probi shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Probi's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Probi's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:PBBI.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2007 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:PBBI.F Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 2.13 2.00
2020-12-31 1.53 2.00
2019-12-31 1.25 2.00
OTCPK:PBBI.F Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2018-11-01 0.000 0.000
2018-08-13 0.000 0.000
2018-05-02 0.000 0.000
2018-03-29 0.000 0.000
2018-01-25 0.000 0.000
2017-03-30 1.000 0.256
2016-03-30 1.000 0.343
2015-04-23 0.850 0.628
2014-04-07 0.750 1.366
2014-01-23 0.750 1.863
2013-04-25 0.750 1.865
2012-03-27 0.750 1.648
2012-01-25 0.750 1.255
2011-03-16 0.500 1.042
2011-01-26 0.500 1.100
2010-04-12 0.500 0.945
2010-01-27 0.500 0.841

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Probi has not reported any payouts.
  • Unable to verify if Probi's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Probi's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Probi has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Probi's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Probi's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Probi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Probi has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Probi's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom Rönnlund
AGE 46
TENURE AS CEO 0.3 years
CEO Bio

Mr. Tom Rönnlund is Chief Executive Officer at Probi AB (publ) since January 1, 2019. Mr. Rönnlund was the Chief Executive Officer of Navamedic ASA from May 18, 2015 to December 31,2018. Mr. Rönnlund has more than 17 years of business development and general management experience from the international healthcare industry to Navamedic. He joined Navamedic from IMS Health Inc, a global analytics and technology services company focused on the healthcare sector, where he held the position of General Manager for the Nordic & Baltic Region. Prior to joining IMS Health, he has served in sales, marketing and general management roles with biopharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly. Mr. Rönnlund holds a master’s degree in business administration and Economics from Stockholm University.

CEO Compensation
  • Insufficient data for Tom to compare compensation growth.
  • Insufficient data for Tom to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Probi management team in years:

0.6
Average Tenure
48
Average Age
  • The average tenure for the Probi management team is less than 2 years, this suggests a new team.
Management Team

Tom Rönnlund

TITLE
Chief Executive Officer
AGE
46
TENURE
0.3 yrs

Henrik Lundkvist

TITLE
Chief Financial Officer
AGE
41
TENURE
0.3 yrs

Andy McShea

TITLE
Vice President of Global Operations
AGE
48
TENURE
0.6 yrs

Niklas Larsson

TITLE
Lead Scientific Affairs
AGE
48
TENURE
0.6 yrs

Steve Prescott

TITLE
Vice President of Marketing
AGE
48
TENURE
1.3 yrs

Niklas Brandt

TITLE
Vice President of HR & IT
AGE
59
TENURE
1.3 yrs

Anna-Karin Robertson

TITLE
Head of Discovery

Magdolna Dimén

TITLE
Group Controller

Linda Neckmar

TITLE
VP of EMEA & APAC
AGE
45
Board of Directors Tenure

Average tenure and age of the Probi board of directors in years:

4.1
Average Tenure
55
Average Age
  • The tenure for the Probi board of directors is about average.
Board of Directors

Jean-Yves Parisot

TITLE
Chairman
COMPENSATION
SEK375K
AGE
54
TENURE
4.1 yrs

Jan Nilsson

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
SEK194K
AGE
65

Charlotte Hansson

TITLE
Director
COMPENSATION
SEK150K
AGE
56
TENURE
2 yrs

Lars Gatenbeck

TITLE
Member of Scientific Advisory Board

Hans Wigzell

TITLE
Member of Scientific Advisory Board
AGE
80

Jörn Andreas

TITLE
Director
COMPENSATION
SEK29K
AGE
38

Jonny Olsson

TITLE
Director
COMPENSATION
SEK194K
AGE
54
TENURE
4.1 yrs

Glenn Gibson

TITLE
Member of Scientific Advisory Board

Maria Rescigno

TITLE
Member of Scientific Advisory Board

Henrik Vestergaard

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Probi insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. May 19 Buy Tom Rönnlund Individual 02. May 19 02. May 19 1,000 $38.33 $38,326
02. May 19 Buy Henrik Lundkvist Individual 02. May 19 02. May 19 150 $37.70 $5,656
X
Management checks
We assess Probi's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Probi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies. The company operates in two segments, Consumer Healthcare and Functional Food. It conducts research primarily in the fields of digestive health, immune response, and nutrient absorption. The company provides probiotics in the form of powder, capsules, tablets, and fruit juice drinks. It sells its products in approximately 40 countries worldwide. Probi AB (publ) has a development agreement with Cilag GmbH International for the development of probiotic products. The company was founded in 1991 and is headquartered in Lund, Sweden.

Details
Name: Probi AB (publ)
PBBI.F
Exchange: OTCPK
Founded: 1991
SEK416,402,223
11,394,125
Website: http://www.probi.com
Address: Probi AB (publ)
Sölvegatan 41A,
Lund,
Skåne County, 223 70,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM PROB Common Shares OMX Nordic Exchange Stockholm SE SEK 01. Nov 2004
OTCPK PBBI.F Common Shares Pink Sheets LLC US USD 01. Nov 2004
LSE 0GZB Common Shares London Stock Exchange GB SEK 01. Nov 2004
BATS-CHIXE PROBS Common Shares BATS 'Chi-X Europe' GB SEK 01. Nov 2004
Number of employees
Current staff
Staff numbers
165
Probi employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/27 00:46
End of day share price update: 2019/05/07 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/04/29
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.